HDAC5 Protein

Histone Deacetylase 5

Overview

HDAC5 (Histone Deacetylase 5) is a Class IIa histone deacetylase that functions as a signal-dependent transcriptional regulator^{1The many roles of histone deacetylases in development and physiology: implications for disease and therapy2009 · Nature Reviews Genetics · PMID 19065135Open reference}. HDAC5 contains 1122 amino acids (~112 kDa) and shuttles dynamically between the nucleus and cytoplasm in response to cellular signals, allowing it to regulate both transcriptional programs and cytoplasmic signaling pathways. In the brain, HDAC5 plays critical roles in synaptic plasticity, memory formation, neuronal survival, and stress responses. Dysregulation of HDAC5 has been implicated in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, making it an attractive therapeutic target^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}.

Protein Structure

Domain Architecture

HDAC5 contains three major structural domains^{3The Rpd3/Hda1 family of histone deacetylases2003 · Nature Reviews Molecular Cell Biology · PMID 12881426Open reference4HDAC5 structure and function: molecular basis for pharmacological intervention2020 · Journal of Medicinal Chemistry · PMID 32195523Open reference}:

N-terminal Regulatory Domain (aa 1-421):

• Contains binding sites for transcription factors (MEF2, REST)

• Interacts with 14-3-3 chaperone proteins

• Multiple phosphorylation sites for signal-dependent regulation

• Docking site for kinases (CaMK, PKD, PKA)

• CRM1-dependent nuclear export signal

Catalytic Domain (aa 482-680):

• Zinc-dependent deacetylase active site

• Class IIa HDACs have lower catalytic activity than Class I enzymes

• Requires association with HDAC3 for full repression activity

• Contains structural features that accommodate Class IIa-specific substrates

C-terminal Domain (aa 682-1022):

• Additional phosphorylation regulatory sites

• NLS (nuclear localization signal) sequences

• HDAC3-binding interface

• Dimerization capability

Post-Translational Modifications

HDAC5 is extensively regulated by post-translational modifications that control its localization and activity^{5Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation2000 · Nature · PMID 11081517Open reference6Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization2000 · Proceedings of the National Academy of Sciences · PMID 10869435Open reference}:

Modification	Site	Kinase/Enzyme	Effect
Phosphorylation	Ser259	CaMK, AMPK	Creates 14-3-3 binding site, promotes nuclear export
Phosphorylation	Ser498	CaMK, AMPK	Creates 14-3-3 binding site, promotes nuclear export
Phosphorylation	Ser310	PKD	Regulates nuclear-cytoplasmic shuttling
Phosphorylation	Ser275	PKA	Modulates subcellular localization
Acetylation	Lys559	p300/CBP	Alters HDAC5 transcriptional repressive activity
SUMOylation	Lys899	SUMO E3 ligases	Modulates protein interactions
Ubiquitination	Multiple	E3 ligases	Proteasomal degradation

3D Structure

Crystal structures of the HDAC4/5 catalytic domain (PDB: 2VQM) reveal^{4HDAC5 structure and function: molecular basis for pharmacological intervention2020 · Journal of Medicinal Chemistry · PMID 32195523Open reference}:

• Rossmann-fold catalytic core with zinc ion at the active site

• Class IIa characteristic shallow, elongated binding pocket

• Two coordinated water molecules at the active site explaining reduced deacetylase activity

• Conformational flexibility important for substrate recognition

Molecular Function

Catalytic Activity

HDAC5 catalyzes the removal of acetyl groups from lysine residues, though with different substrate specificity than Class I HDACs^{1The many roles of histone deacetylases in development and physiology: implications for disease and therapy2009 · Nature Reviews Genetics · PMID 19065135Open reference}:

Histone substrates:

• H3K9, H3K14, H4K5 (weak deacetylation activity)

• Histone deacetylation promotes chromatin compaction and transcriptional repression

Non-histone substrates:

• Transcription factors (p53, MEF2, NF-κB)

• Signaling proteins (14-3-3 proteins, kinases)

• Cytoskeletal proteins (actin, tubulin)

Mechanism: Zinc-dependent hydrolysis of acetyl-lysine side chains

Signal-Dependent Nuclear-Cytoplasmic Shuttling

HDAC5 is a paradigmatic signal-regulated deacetylase^{5Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation2000 · Nature · PMID 11081517Open reference}:

Nucleus-to-Cytoplasm transport:

• CaMK-dependent phosphorylation of Ser259/498

• 14-3-3 protein binding to phosphorylated HDAC5

• CRM1-mediated nuclear export

• Results in relief of transcriptional repression

Cytoplasm-to-Nucleus transport:

• Protein phosphatases (PP1, PP2A) dephosphorylate HDAC5

• 14-3-3 release allows nuclear re-entry

• NLS-mediated nuclear import

• Restores transcriptional repression at target genes

Integration with neuronal activity:

• Elevated intracellular calcium activates CaMK

• Synaptic activity triggers HDAC5 nuclear export

• Activity-dependent gene expression changes

• Links environmental signals to chromatin state

Transcriptional Repression

HDAC5 represses gene transcription through multiple mechanisms^{7Histone acetylation: molecular mnemonics on chromatin2013 · Progress in Brain Research · PMID 23225131Open reference}:

1. Direct chromatin modification:

• Histone deacetylation at target gene promoters

• Recruitment of additional repressive modifiers

• Creation of transcriptionally silent chromatin

2. Transcription factor interactions:

• MEF2 binding and repression

• REST complex recruitment

• NF-κB inhibition

• p53 modulation

3. Corepressor complex formation:

• HDAC3/NCoR/SMRT complexes

• Sin3A co-repressor complexes

• NuRD complexes

Role in Neurodegeneration

Alzheimer’s Disease

HDAC5 alterations contribute to AD pathogenesis through multiple mechanisms^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}0^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}1:

Transcriptional dysregulation:

• Altered HDAC5 nuclear/cytoplasmic ratio in AD patient brains

• Reduced expression of memory-related genes (BDNF, Arc, c-Fos)

• Contributes to synaptic plasticity deficits

Amyloid-beta effects:

• Aβ oligomers alter HDAC5 phosphorylation and localization

• Aβ-induced calcium dysregulation affects HDAC5 nuclear shuttling

• Promotes HDAC5 nuclear export in affected neurons

Tau pathology connections:

• HDAC5 interacts with tau phosphorylation through GSK3β and CDK5

• Tau pathology is associated with altered HDAC5 distribution

• Bidirectional relationship between tau and HDAC5 dysregulation

Therapeutic potential:

• HDAC inhibitors show cognitive enhancement in AD models

• HDAC5-selective modulators represent a promising approach

• Brain penetration remains a challenge for clinical development

Parkinson’s Disease

In Parkinson’s disease^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}2:

Dopaminergic neuron vulnerability:

• HDAC5 affects survival of substantia nigra dopaminergic neurons

• Altered HDAC5 localization in PD models

• Contributes to transcriptional dysfunction

Alpha-synuclein interactions:

• α-Synuclein aggregates induce HDAC5 nuclear export

• Nuclear HDAC5 redistribution in α-synuclein overexpressing cells

• May contribute to transcriptional dysregulation in PD

Neuroprotective potential:

• HDAC5 modulators show neuroprotective effects in PD models

• May enhance expression of neuroprotective genes

• Therapeutic targeting under active investigation

Huntington’s Disease

HDAC5 is a compelling therapeutic target in Huntington’s disease^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}3^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}4:

Mutant huntingtin effects:

• Mutant huntingtin alters HDAC5 localization and function

• HDAC5 mislocalization contributes to transcriptional dysfunction

• Mutant HTT sequesters HDAC4/5 in the cytoplasm

Therapeutic benefit:

• HDAC inhibitor 4b improves phenotypes in HD mouse models

• HDAC5 reduction or inhibition reduces mutant HTT toxicity

• Restores expression of brain-derived neurotrophic factor (BDNF)

• Corrects HDAC5-regulated gene expression programs

Mechanisms:

• Restoring neuronal survival pathways

• Reducing mutant HTT-induced transcriptional repression

• Modulating astrocyte and microglial function

Therapeutic Targeting

HDAC Inhibitors

Pan-HDAC inhibitors have shown therapeutic potential in neurodegeneration models^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}5:

Drug	HDAC Selectivity	Status	Neurological Use
Vorinostat (SAHA)	Pan-HDAC	Approved (CTCL)	Preclinical in AD/PD/HD
Entinostat (MS-275)	HDAC1/2/3	Clinical trials	AD/HD models
Romidepsin	Pan-HDAC	Approved (CTCL)	Preclinical
Trichostatin A	Class I/II	Research only	Proof-of-concept
PCI-34051	HDAC8	Preclinical	HDAC5 indirectly affected

Class IIa-Selective Approaches

Class IIa HDAC-selective compounds offer potential advantages^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}6:

Development status:

• Few selective HDAC4/5 inhibitors exist

• TP-138 studied in oncology

• New scaffolds being explored for CNS applications

• Natural products (e.g., garcinol) show Class IIa activity

Advantages:

• Reduced Class I-mediated toxicity

• More specific gene regulation

• Better therapeutic window for chronic CNS diseases

Challenges:

• Achieving brain penetration

• Selectivity over Class I HDACs

• Understanding optimal mechanism (inhibition vs. modulation)

Interactions and Pathways

Key Protein Interactions

HDAC5 interacts with numerous proteins to execute its functions^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}7^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}8:

Partner	Interaction Domain	Functional Consequence
MEF2A/C	N-terminal (aa 1-200)	Transcriptional repression of MEF2 targets
REST	N-terminal	Neuronal gene repression
NF-κB (p65)	N-terminal	Inflammatory gene suppression
HDAC3	Catalytic domain (aa 500-680)	Corepressor complex formation
NCoR/SMRT	N-terminal	Transcriptional repression complex
14-3-3 proteins	C-terminal (phospho-Ser259/498)	Cytoplasmic retention
CaMK	Cytoplasmic	Phosphorylation and nuclear export
PKD	Cytoplasmic	Phosphorylation and nuclear export
CRM1	C-terminal	Nuclear export

Key Signaling Pathways

MEF2 Pathway:

• HDAC5 represses MEF2-dependent transcription of synaptic genes

• MEF2 regulates neuronal survival, differentiation, and plasticity

• MEF2-HDAC5 balance critical for memory formation

CREB Pathway:

• Cross-talk with CREB-mediated transcription

• Affects BDNF and activity-regulated genes

• Activity-dependent regulation of plasticity genes

NF-κB Pathway:

• HDAC5 inhibits NF-κB transcriptional activity

• Suppresses inflammatory gene expression

• Anti-inflammatory potential in neurodegeneration

p38 MAPK Pathway:

• HDAC5 represses p38 MAPK signaling through MAPK14 targeting^{2HDAC5: a promising therapeutic target in neurodegenerative diseases2022 · Frontiers in Aging Neuroscience · DOI 10.3389/fnagi.2022.852540Open reference}9

• Affects cellular stress responses

• Modulates neuroinflammatory pathways

Expression and Localization

Brain Regional Expression

HDAC5 shows specific patterns of expression in the brain^{3The Rpd3/Hda1 family of histone deacetylases2003 · Nature Reviews Molecular Cell Biology · PMID 12881426Open reference}0:

High expression regions:

• Cerebral cortex (particularly layer 5 pyramidal neurons)

• Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells

• Basal ganglia: Striatum (medium spiny neurons), globus pallidus

• Cerebellum: Purkinje cells

• Amygdala

Cellular localization:

• Both neuronal and glial cell expression

• Nuclear localization in resting neurons

• Activity-dependent nuclear-cytoplasmic shuttling

• Cell type-specific patterns

Animal Models

Knockout and Knockdown Models

HDAC5 global knockout:

• Viable with no major developmental abnormalities

• Enhanced memory formation and synaptic plasticity

• Altered cardiac development (mild)

• Increased anxiety-like behavior in some contexts

Neuron-specific knockdown:

• Enhanced learning and memory in contextual fear conditioning

• Increased dendritic spine density

• Altered synaptic gene expression

• Enhanced hippocampal synaptic plasticity

Disease Model Studies

AD models (APP/PS1, 3xTg-AD):

• HDAC5 changes correlate with cognitive deficits

• Response to HDAC inhibitor treatment

• Altered nuclear/cytoplasmic distribution

PD models (MPTP, 6-OHDA, alpha-synuclein transgenic):

• HDAC5 alterations in dopaminergic neurons

• Neuroprotective effects of HDAC5 modulation

• Role in alpha-synuclein toxicity response

HD models (N171-82Q, R6/1):

• Mutant HTT alters HDAC5 localization

• HDAC5 modulation improves disease phenotypes

• Restores BDNF expression in striatum

See Also

• HDAC5 Gene — Gene page with genomic information

• HDAC4 Protein — Related Class IIa HDAC

• HDAC Enzymes — HDAC family overview

• Alzheimer’s Disease — AD disease page

• Parkinson’s Disease — PD disease page

• Huntington’s Disease — HD disease page

• HDAC Inhibitors — Therapeutic agents

• Epigenetics in Neurodegeneration — Epigenetic mechanisms